DOM-URSODIOL C TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
23-04-2013
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
URSODIOL
Tillgänglig från:
DOMINION PHARMACAL
ATC-kod:
A05AA02
INN (International namn):
URSODEOXYCHOLIC ACID
Dos:
250MG
Läkemedelsform:
TABLET
Sammansättning:
URSODIOL 250MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
CHOLELITHOLYTIC AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0122789001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2006-08-10
Produktens egenskaper
PRODUCT MONOGRAPH
PR
DOM-URSODIOL C
Ursodiol Tablets USP
250 mg & 500 mg
CHOLESTATIC LIVER DISEASES
DOMINION PHARMACAL
DATE OF REVISION:
6111 Royalmount Avenue, Suite 100
April 23, 2013
Montreal, Quebec H4P 2T2
CONTROL NUMBER: 163339
_ _
_Dom-URSODIOL C Product Monograph _
_Page 2 of 29_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS..........................................................................................................
5
DRUG INTERACTIONS
........................................................................................................
10
DOSAGE AND ADMINISTRATION
....................................................................................
11
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 11
STORAGE AND STABILITY
................................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
.............................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
.....................................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................
14
CLINICAL TRIALS
.....................................................................................................
Läs hela dokumentet
